Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0MPDIB
ADC Name	ABBV-154
Synonyms	ABBV 154; ABBV154 Click to Show/Hide
Organization	AbbVie, Inc.
Drug Status	Phase 2
Indication	In total 3 Indication(s) Crohn disease [ICD11:DD70] Phase 2 Polymyalgia rheumatica [ICD11:FA22] Phase 2 Rheumatoid arthritis [ICD11:FA20] Phase 2
Drug-to-Antibody Ratio	4
Structure
	3D MOL	2D MOL
Antibody Name	Adalimumab		Antibody Info
Antigen Name	Tumor necrosis factor (TNF)		Antigen Info
Payload Name	Glucocorticoid receptor modulator		Payload Info
Therapeutic Target	Glucocorticoid receptor (NR3C1)		Target Info
Linker Name	Formyl-Gly-Glu		Linker Info
Conjugate Type	Random conjugation through reduced inter-chain cysteines.

General Information of The Activity Data Related to This ADC

Identified from the Human Clinical Data

Click To Hide/Show 4 Activity Data Related to This Level

Standard Type	NCT Number	Clinical Status	Clinical Trial Description
Undisclosed	NCT05068284	Phase 2	A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of ABBV-154 in subjects with moderately to severely active crohn's disease (CD): aim-cd.
Undisclosed	NCT04972968	Phase 2	A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety and efficacy of ABBV-154 in subjects with polymyalgia rheumatica (PMR) dependent on glucocorticoid treatment. Click to Show/Hide
Undisclosed	NCT04888585	Phase 2	A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of ABBV-154 in subjects with moderately to severely active rheumatoid arthritis with inadequate response to biologic and/or targeted synthetic disease-modifying anti-rheumatic drugs (b/tsdmards). Click to Show/Hide
Undisclosed	NCT05556226	Phase 1	A phase 1 study in healthy subjects to evaluate the relative bioavailability of ABBV-154.

Full List of Activity Data of This Antibody-drug Conjugate

Identified from the Human Clinical Data

Click To Hide/Show 4 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
*Related Clinical Trial*
NCT Number	NCT05068284	Clinical Status	Phase 2
Clinical Description	A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of ABBV-154 in subjects with moderately to severely active crohn's disease (CD): aim-cd.
Experiment 2 Reporting the Activity Date of This ADC				[2]
*Related Clinical Trial*
NCT Number	NCT04972968	Clinical Status	Phase 2
Clinical Description	A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety and efficacy of ABBV-154 in subjects with polymyalgia rheumatica (PMR) dependent on glucocorticoid treatment.
Experiment 3 Reporting the Activity Date of This ADC				[3]
*Related Clinical Trial*
NCT Number	NCT04888585	Clinical Status	Phase 2
Clinical Description	A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of ABBV-154 in subjects with moderately to severely active rheumatoid arthritis with inadequate response to biologic and/or targeted synthetic disease-modifying anti-rheumatic drugs (b/tsdmards).
Experiment 4 Reporting the Activity Date of This ADC				[4]
*Related Clinical Trial*
NCT Number	NCT05556226	Clinical Status	Phase 1
Clinical Description	A phase 1 study in healthy subjects to evaluate the relative bioavailability of ABBV-154.

References

Ref 1	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Moderately to Severely Active Crohn's Disease (CD): AIM-CD, NCT05068284
Ref 2	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, NCT04972968
Ref 3	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response to Biologic and/or Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs (b/tsDMARDs), NCT04888585
Ref 4	A Phase 1 Study in Healthy Subjects to Evaluate the Relative Bioavailability of ABBV-154, NCT05556226